These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35105718)

  • 1. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
    Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
    Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
    Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
    Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
    JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N; Lee JM; Shah K; Wakimoto H
    Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
    Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
    Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
    J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
    Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
    Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKR induces TGF-β and limits oncolytic immune therapy.
    Hong B; Sahu U; Mullarkey MP; Hong E; Pei G; Yan Y; Otani Y; Banasavadi-Siddegowda Y; Fan H; Zhao Z; Yu J; Caligiuri MA; Kaur B
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.
    Noh MH; Kang JM; Miller AA; Nguyen G; Huang M; Shim JS; Bueso-Perez AJ; Murphy SA; Rivera-Caraballo KA; Otani Y; Kim E; Yoo SH; Yan Y; Banasavadi-Siddegowda Y; Nakashima H; Chiocca EA; Kaur B; Zhao Z; Lee TJ; Yoo JY
    Neuro Oncol; 2024 Sep; 26(9):1602-1616. PubMed ID: 38853689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
    Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
    Reale A; Gatta A; Shaik AKB; Shallak M; Chiaravalli AM; Cerati M; Zaccaria M; La Rosa S; Calistri A; Accolla RS; Forlani G
    J Transl Med; 2024 Sep; 22(1):862. PubMed ID: 39334370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.
    Otani Y; Yoo JY; Lewis CT; Chao S; Swanner J; Shimizu T; Kang JM; Murphy SA; Rivera-Caraballo K; Hong B; Glorioso JC; Nakashima H; Lawler SE; Banasavadi-Siddegowda Y; Heiss JD; Yan Y; Pei G; Caligiuri MA; Zhao Z; Chiocca EA; Yu J; Kaur B
    Clin Cancer Res; 2022 Apr; 28(7):1460-1473. PubMed ID: 35022322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
    Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
    Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
    Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
    PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
    Friedman GK; Bernstock JD; Chen D; Nan L; Moore BP; Kelly VM; Youngblood SL; Langford CP; Han X; Ring EK; Beierle EA; Gillespie GY; Markert JM
    Sci Rep; 2018 Sep; 8(1):13930. PubMed ID: 30224769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.